Program
empasiprubart
Also written as “Empasiprubart IV”, “ARGX-117” and “Empasiprubart”.
Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Dermatomyositis · Myasthenia Gravis · Guillain-Barre Syndrome · Delayed Graft Function, led by argenx.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 1310 open or running | phase 3since Dec 16, 2024 | Aug 26, 2020 | Nov 2026phase 2 · NCT06284954 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04532125 · 110 enrolled · Netherlands
- Nov 5, 2021Phase 2 study in Multifocal Motor NeuropathyNCT05225675 · 54 enrolled · United States, Austria, Belgium and more
- May 17, 2022Phase 2 study in Multifocal Motor Neuropathy (MMN)NCT05405361 · 51 enrolled · United States, Austria, Belgium and more
- Jun 8, 2023Phase 2 study in Delayed Graft FunctionNCT05907096 · 103 enrolled · United States, Australia, Austria and more
- Feb 22, 2024Phase 2 study in DermatomyositisNCT06284954 · 3 enrolled · United States, Georgia, Greece and more
- Dec 16, 2024Phase 3 study in Multifocal Motor Neuropathy (MMN)NCT06742190 · 154 enrolled · United States, Australia, Austria and more
- Mar 26, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06920004 · 218 planned · United States, Argentina, Australia and more
- Jul 22, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07091630 · 160 planned · United States, Argentina, Austria and more
- May 20, 20262 phase 1 studiesNCT07610564, NCT07612020
- Jun 5, 2026Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07638566
- Jun 23, 2026Phase 2 study in Myasthenia GravisNCT07673627 · 40 planned · United States, Belgium, Greece and more
- Sep 10, 2026Phase 2 study in Guillain-Barre SyndromeNCT07821762 · 63 planned
- Nov 13, 2026Phase 3 study withdrawnStudy stoppedNCT07638566 · “An alternative study design is under consideration.”
Ahead
- Nov 2026Primary completion: phase 2 study in DermatomyositisNCT06284954
- Mar 2027Primary completion: phase 1 study in Healthy VolunteersNCT07612020
- Sep 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06920004
- Oct 2027Primary completion: phase 2 study in Myasthenia GravisNCT07673627
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07821762Guillain-Barre Syndrome | 2 | Not yet recruiting | Jan 2028 | 63 |
| NCT07673627Myasthenia Gravis · United States, Belgium, Greece and more | 2 | Recruiting | Oct 2027 | 40 |
| NCT07638566Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 3 | Withdrawn | Apr 2028 | 0 |
| NCT07612020Healthy Volunteers · Canada | 1 | Recruiting | Mar 2027 | 130 |
| NCT07610564Multifocal Motor Neuropathy (MMN) · United States, Georgia | 1 | Recruiting | Feb 1, 2028 | 60 |
| NCT07091630Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Austria and more | 3 | Recruiting | Oct 7, 2027 | 160 |
| NCT06920004Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more | 3 | Recruiting | Sep 2027 | 218 |
| NCT06742190Multifocal Motor Neuropathy (MMN) · United States, Australia, Austria and more | 3 | Active, not recruiting | Sep 2026 | 154 |
| NCT06284954Dermatomyositis · United States, Georgia, Greece and more | 2 | Active, not recruiting | Nov 2026 | 3 |
| NCT05907096Delayed Graft Function · United States, Australia, Austria and more | 2 | Active, not recruiting | Oct 16, 2025 | 103 |
| NCT05405361Multifocal Motor Neuropathy (MMN) · United States, Austria, Belgium and more | 2 | Active, not recruiting | Sep 30, 2029 | 51 |
| NCT05225675Multifocal Motor Neuropathy · United States, Austria, Belgium and more | 2 | Completed | Jun 4, 2024 | 54 |
| NCT04532125Healthy Volunteers · Netherlands | 1 | Completed | Aug 26, 2022 | 110 |
How it is read
Names in the registry
- “Empasiprubart IV”, 6 entries
- “ARGX-117”, 4 entries
- “empasiprubart”, 1 entry
- “Empasiprubart”, 1 entry
- “empasiprubart IV”, 1 entry
Conditions, from the studies’ own filings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 3 studies
- Dermatomyositis, 1 study
- Myasthenia Gravis, 1 study
- Guillain-Barre Syndrome, 1 study
- Delayed Graft Function, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.